PMID- 34743292
OWN - NLM
STAT- MEDLINE
DCOM- 20220331
LR  - 20220331
IS  - 1559-1182 (Electronic)
IS  - 0893-7648 (Linking)
VI  - 59
IP  - 1
DP  - 2022 Jan
TI  - Dendritic Cell-Targeted Therapies to Treat Neurological Disorders.
PG  - 603-619
LID - 10.1007/s12035-021-02622-4 [doi]
AB  - Dendritic cells (DCs) are the immune system's highly specialized 
      antigen-presenting cells. When DCs are sluggish and mature, self-antigen 
      presentation results in tolerance; however, when pathogen-associated molecular 
      patterns stimulate mature DCs, antigen presentation results in the development of 
      antigen-specific immunity. DCs have been identified in various vital organs of 
      mammals (e.g., the skin, heart, lungs, intestines, and spleen), but the brain has 
      long been thought to be devoid of DCs in the absence of neuroinflammation. 
      However, neuroinflammation is becoming more recognized as a factor in a variety 
      of brain illnesses. DCs are present in the brain parenchyma in trace amounts 
      under healthy circumstances, but their numbers rise during neuroinflammation. New 
      therapeutics are being developed that can reduce dendritic cell immunogenicity by 
      inhibiting pro-inflammatory cytokine production and T cell co-stimulatory 
      pathways. Additionally, innovative ways of regulating dendritic cell growth and 
      differentiation and harnessing their tolerogenic capability are being explored. 
      Herein, we described the function of dendritic cells in neurological disorders 
      and discussed the potential for future therapeutic techniques that target 
      dendritic cells and dendritic cell-related targets in the treatment of 
      neurological disorders.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Hussain, Asim
AU  - Hussain A
AD  - Department of Biochemistry, Riphah International University, Faisalabad, 38040, 
      Pakistan.
FAU - Rafeeq, Hamza
AU  - Rafeeq H
AD  - Department of Biochemistry, Riphah International University, Faisalabad, 38040, 
      Pakistan.
FAU - Munir, Nimra
AU  - Munir N
AD  - Department of Biochemistry, University of Agriculture, Faisalabad, 38040, 
      Pakistan.
FAU - Jabeen, Zara
AU  - Jabeen Z
AD  - Department of Biochemistry, Riphah International University, Faisalabad, 38040, 
      Pakistan.
FAU - Afsheen, Nadia
AU  - Afsheen N
AD  - Department of Biochemistry, Riphah International University, Faisalabad, 38040, 
      Pakistan.
FAU - Rehman, Khalil Ur
AU  - Rehman KU
AD  - Department of Biochemistry, Riphah International University, Faisalabad, 38040, 
      Pakistan.
FAU - Bilal, Muhammad
AU  - Bilal M
AD  - School of Life Science and Food Engineering, Huaiyin Institute of Technology, 
      Huaian, 223003, China. bilaluaf@hyit.edu.cn.
FAU - Iqbal, Hafiz M N
AU  - Iqbal HMN
AD  - Tecnologico de Monterrey, School of Engineering and Sciences, 64849, Monterrey, 
      Mexico. hafiz.iqbal@tec.mx.
LA  - eng
GR  - CVU: 735340/sistema nacional de investigadores/
PT  - Journal Article
PT  - Review
DEP - 20211106
PL  - United States
TA  - Mol Neurobiol
JT  - Molecular neurobiology
JID - 8900963
SB  - IM
MH  - Animals
MH  - Dendritic Cells/*drug effects
MH  - *Drug Delivery Systems
MH  - Humans
MH  - *Immune Tolerance
MH  - Nervous System Diseases/*drug therapy/immunology
OTO - NOTNLM
OT  - Dendritic cells
OT  - Dendritic cell-targeted therapies
OT  - Disease-specific therapies
OT  - Drug delivery systems
OT  - Neurological disorders
EDAT- 2021/11/08 06:00
MHDA- 2022/04/01 06:00
CRDT- 2021/11/07 20:48
PHST- 2021/06/17 00:00 [received]
PHST- 2021/10/26 00:00 [accepted]
PHST- 2021/11/08 06:00 [pubmed]
PHST- 2022/04/01 06:00 [medline]
PHST- 2021/11/07 20:48 [entrez]
AID - 10.1007/s12035-021-02622-4 [pii]
AID - 10.1007/s12035-021-02622-4 [doi]
PST - ppublish
SO  - Mol Neurobiol. 2022 Jan;59(1):603-619. doi: 10.1007/s12035-021-02622-4. Epub 2021 
      Nov 6.